Company / Shareholders' Equity
Veracyte, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.3B
FY2025
5-year range
$1.0B / $1.3B
FY2021-FY2025
Trend
+11.4%
vs FY2024
Sector context
#76 of 166
Health Care
What the data says
At $1.3B, Veracyte, Inc.'s shareholders' equity ranks #76 of 166 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $37M in FY2017 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +25.5%.
Improved from $1.0B to $1.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +6.8%
- 5-Year CAGR
- +25.5%
- 10-Year CAGR
- -
Sector benchmark
#76 of 166 in Health CareTop 46% of 166This company $1.3B Sector average $5.3B
▼
-75.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 11.4% year-over-year.
- Ranks #76 out of 166 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +11.4% |
| FY2024 | $1.2B | +12.6% |
| FY2023 | $1.0B | -2.9% |
| FY2022 | $1.1B | -1.9% |
| FY2021 | $1.1B | +160.3% |
| FY2020 | $421.2M | +75.9% |
| FY2019 | $239.5M | +200.2% |
| FY2018 | $79.8M | +114.3% |
| FY2017 | $37.2M | -37.5% |
| FY2016 | $59.6M | +16.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026